Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo HEP potency determination of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts
2013-005394-45Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Jul 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dermatophagoides pteronyssinus and dermatophagoides farinae allergen extract in house dust mite allergy, Dermatophagoides farinae allergy, allergic rhinitis (AR) and 2 more (2 arms), sponsored by Inmunotek. Primary endpoint: Potency equivalence objective. Started Jul 2015; status: completed.
02
Drugs
dermatophagoides pteronyssinusdermatophagoides farinae allergen extract
03
Conditions
house dust mite allergyDermatophagoides farinae allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2013-005394-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005394-45.